Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler Sells 1,985 Shares

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 1,985 shares of the stock in a transaction on Friday, July 12th. The shares were sold at an average price of $12.53, for a total value of $24,872.05. Following the sale, the general counsel now owns 485,676 shares in the company, valued at approximately $6,085,520.28. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Russell Schundler also recently made the following trade(s):

• On Monday, June 3rd, Russell Schundler sold 710 shares of Liquidia stock. The shares were sold at an average price of $14.55, for a total value of $10,330.50.

Liquidia Price Performance

Shares of NASDAQ:LQDA traded down $0.17 on Monday, hitting $12.44. 679,382 shares of the company’s stock were exchanged, compared to its average volume of 866,789. The business’s 50 day simple moving average is $12.73 and its two-hundred day simple moving average is $13.45. The stock has a market capitalization of $950.54 million, a price-to-earnings ratio of -7.97 and a beta of 0.32. Liquidia Co. has a 12 month low of $5.71 and a 12 month high of $16.99.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.22). The firm had revenue of $2.97 million during the quarter, compared to the consensus estimate of $4.31 million. Liquidia had a negative net margin of 674.42% and a negative return on equity of 177.83%. Equities analysts forecast that Liquidia Co. will post -1.32 EPS for the current fiscal year.

Institutional Trading of Liquidia

Several institutional investors and hedge funds have recently made changes to their positions in LQDA. Vanguard Group Inc. boosted its position in Liquidia by 1.0% during the third quarter. Vanguard Group Inc. now owns 2,774,398 shares of the company’s stock valued at $17,590,000 after purchasing an additional 26,678 shares in the last quarter. Fortitude Family Office LLC bought a new stake in Liquidia during the fourth quarter valued at about $26,000. SG Americas Securities LLC boosted its position in Liquidia by 17.4% during the fourth quarter. SG Americas Securities LLC now owns 15,540 shares of the company’s stock valued at $187,000 after purchasing an additional 2,298 shares in the last quarter. Bleakley Financial Group LLC boosted its position in Liquidia by 45.6% during the fourth quarter. Bleakley Financial Group LLC now owns 31,193 shares of the company’s stock valued at $375,000 after purchasing an additional 9,764 shares in the last quarter. Finally, LB Partners LLC bought a new stake in Liquidia during the fourth quarter valued at about $3,404,000. 64.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Liquidia in a research note on Wednesday, July 10th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of Liquidia in a research report on Monday, June 3rd. Finally, Oppenheimer assumed coverage on Liquidia in a research report on Tuesday, June 25th. They set a “market perform” rating for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Liquidia currently has an average rating of “Moderate Buy” and an average price target of $21.60.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).